Detalles de la búsqueda
1.
Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R-MIV) in patients with primary CNS lymphoma including recent COVID-19 pandemic experience.
Br J Haematol
; 201(4): 663-672, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36762710
2.
Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma.
Br J Haematol
; 198(1): 73-81, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35362096
3.
Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
Am J Ther
; 23(3): e749-56, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-24732904
4.
High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up.
Sci Rep
; 12(1): 10551, 2022 06 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35732790
5.
Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.
Adv Med Sci
; 65(2): 371-377, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32659728
6.
Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.
Anticancer Res
; 40(7): 4059-4066, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32620653
7.
Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.
Adv Med Sci
; 64(2): 349-355, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31125864
8.
FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma.
Leuk Lymphoma
; 52(8): 1604-6, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21657954
Resultados
1 -
8
de 8
1
Próxima >
>>